DOI: 10.4244/EIJ-D-18-00236L

Extended benefits of TAVR in young patients with low-intermediate risk score: proceed with care

Rajkumar Doshi, MD, MPH

I read with great interest the article “In-hospital outcomes after transcatheter or surgical aortic valve replacement in younger patients less than 75 years old: a propensity-matched comparison” by Eggebrecht et al1. The authors revealed similar in-hospital mortality and stroke rates in the propensity score-matched transfemoral-transcatheter aortic valve replacement (TF-TAVR) and surgical aortic valve replacement (SAVR) patients. However, need for permanent pacemaker rates were fourfold higher with TF-TAVR. This study is of significant importance since the indications for TAVR have been increasing following the SURTAVI trial2.

I have a few concerns regarding this study. First, more low-risk patients were included in the SAVR group (95% versus 55%) prior to the matching. Second, after propensity score matching, the standardised difference was 78.7% between the groups (p<0.001) with almost double in the TF-TAVR group. This could be one of the reasons for comparable mortality with TF-TAVR and SAVR in this study. Third, other routes for performing TAVR have been expanding which may include direct-aortic, subclavian, or carotid approach. These alternatives could be associated with higher success rates and lower complication rates3. Finally, the type of valve is not mentioned in this article. Valve design has been improving to reduce paravalvular leak post TAVR4. Additionally, the prevalence of the anatomy of the valve (bicuspid or tricuspid) is not described in this paper. Although the prevalence of bicuspid valves is more common in these young patients5, the decision to perform TAVR should be carefully weighed, keeping all the benefits and risks in mind.

In conclusion, TAVR techniques are improving with its increasing indications. Young patients may receive benefits from TAVR; however, we need to determine best practices in relation to the benefits for our patients based on the observational database until more robust randomised control trial results are presented.

Conflict of interest statement

The author has no conflicts of interest to declare.


References

Volume 14 Number 4
Jul 20, 2018
Volume 14 Number 4
View full issue


Key metrics

On the same subject

10.4244/EIJV14I1A4 May 20, 2018
TAVR in younger patients with aortic stenosis: anything new?
Mack MJ et al
free

10.4244/EIJV14I18A313 Apr 5, 2019
Transcatheter aortic valve implantation in patients at low surgical risk
Søndergaard L et al
free

10.4244/EIJV15I17A268 Apr 17, 2020
Transcatheter aortic valve implantation in nonagenarians – old…but not obsolete!
Grube E and Sinning J
free

10.4244/EIJ-E-21-00010 Mar 18, 2022
TAVR under 70: is age just a number?
Ng VG et al
free

10.4244/EIJV11SWA27 Sep 17, 2015
Patient selection for TAVI 2015 - TAVI in low-risk patients: fact or fiction?
Haussig S and Linke A
free
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved